Literature DB >> 26757161

Sprouty-Related Ena/Vasodilator-Stimulated Phosphoprotein Homology 1-Domain-Containing Protein-2 Critically Regulates Influenza A Virus-Induced Pneumonia.

Toshihiro Ito1, Junya Itakura, Sakuma Takahashi, Miwa Sato, Megumi Mino, Soichiro Fushimi, Masao Yamada, Tuneo Morishima, Steven L Kunkel, Akihiro Matsukawa.   

Abstract

OBJECTIVES: Influenza A virus causes acute respiratory infections that induce annual epidemics and occasional pandemics. Although a number of studies indicated that the virus-induced intracellular signaling events are important in combating influenza virus infection, the mechanism how specific molecule plays a critical role among various intracellular signaling events remains unknown. Raf/MEK/extracellular signal-regulated kinase cascade is one of the key signaling pathways during influenza virus infection, and the Sprouty-related Ena/vasodilator-stimulated phosphoprotein homology 1-domain-containing protein has recently been identified as a negative regulator of Raf-dependent extracellular signal-regulated kinase activation. Here, we examined the role of Raf/MEK/extracellular signal-regulated kinase cascade through sprouty-related Ena/vasodilator-stimulated phosphoprotein homology 1-domain-containing protein in influenza A viral infection because the expression of sprouty-related Ena/vasodilator-stimulated phosphoprotein homology 1-domain-containing protein was significantly enhanced in human influenza viral-induced pneumonia autopsy samples.
DESIGN: Prospective animal trial.
SETTING: Research laboratory.
SUBJECTS: Wild-type and sprouty-related Ena/vasodilator-stimulated phosphoprotein homology 1-domain-containing protein-2 knockout mice inoculated with influenza A.
INTERVENTIONS: Wild-type or sprouty-related Ena/vasodilator-stimulated phosphoprotein homology 1-domain-containing protein-2 knockout mice were infected by intranasal inoculation of influenza A (A/PR/8). An equal volume of phosphate-buffered saline was inoculated intranasally into mock-infected mice.
MEASUREMENTS AND MAIN RESULTS: Influenza A infection of sprouty-related Ena/vasodilator-stimulated phosphoprotein homology 1-domain-containing protein-2 knockout mice led to higher mortality with greater viral load, excessive inflammation, and enhanced cytokine production than wild-type mice. Administration of MEK inhibitor, U0126, improved mortality and reduced both viral load and cytokine levels. Furthermore, bone marrow chimeras indicated that influenza A-induced lung pathology was most severe when sprouty-related Ena/vasodilator-stimulated phosphoprotein homology 1-domain-containing protein-2 expression was lacking in nonimmune cell populations. Furthermore, microarray analysis revealed knockdown of sprouty-related Ena/vasodilator-stimulated phosphoprotein homology 1-domain-containing protein-2 led to enhanced phosphatidylinositol 3-kinase signaling pathway, resulting that viral clearance was regulated by sprouty-related Ena/vasodilator-stimulated phosphoprotein homology 1-domain-containing protein-2 expression through the phosphatidylinositol 3-kinase signaling pathway in murine lung epithelial cells.
CONCLUSIONS: These data support an important function of sprouty-related Ena/vasodilator-stimulated phosphoprotein homology 1-domain-containing protein-2 in controlling influenza virus-induced pneumonia and viral replication. Sprouty-related Ena/vasodilator-stimulated phosphoprotein homology 1-domain-containing protein-2 may be a novel therapeutic target for controlling the immune response against influenza influenza A virus infection.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26757161      PMCID: PMC4911260          DOI: 10.1097/CCM.0000000000001562

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  47 in total

1.  Synthetic retinoid Am80 ameliorates chronic graft-versus-host disease by down-regulating Th1 and Th17.

Authors:  Hisakazu Nishimori; Yoshinobu Maeda; Takanori Teshima; Haruko Sugiyama; Koichiro Kobayashi; Yoshiko Yamasuji; Sachiyo Kadohisa; Hidetaka Uryu; Kengo Takeuchi; Takehiro Tanaka; Tadashi Yoshino; Yoichiro Iwakura; Mitsune Tanimoto
Journal:  Blood       Date:  2011-11-10       Impact factor: 22.113

Review 2.  From the bench to the bed side: PI3K pathway inhibitors in clinical development.

Authors:  Saveur-Michel Maira; Peter Finan; Carlos Garcia-Echeverria
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

Review 3.  Evolution and ecology of influenza A viruses.

Authors:  R G Webster; W J Bean; O T Gorman; T M Chambers; Y Kawaoka
Journal:  Microbiol Rev       Date:  1992-03

Review 4.  Mitogen-activated protein kinase pathways.

Authors:  M J Robinson; M H Cobb
Journal:  Curr Opin Cell Biol       Date:  1997-04       Impact factor: 8.382

5.  Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus.

Authors:  T C Dawson; M A Beck; W A Kuziel; F Henderson; N Maeda
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

Review 6.  Antiviral actions of interferons.

Authors:  C E Samuel
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

Review 7.  Influenza: old and new threats.

Authors:  Peter Palese
Journal:  Nat Med       Date:  2004-12       Impact factor: 53.440

8.  Redox-active protein thioredoxin-1 administration ameliorates influenza A virus (H1N1)-induced acute lung injury in mice.

Authors:  Masato Yashiro; Hirokazu Tsukahara; Akihiro Matsukawa; Mutsuko Yamada; Yosuke Fujii; Yoshiharu Nagaoka; Mitsuru Tsuge; Nobuko Yamashita; Toshihiro Ito; Masao Yamada; Hiroshi Masutani; Junji Yodoi; Tsuneo Morishima
Journal:  Crit Care Med       Date:  2013-01       Impact factor: 7.598

9.  Chemokine expression during the development and resolution of a pulmonary leukocyte response to influenza A virus infection in mice.

Authors:  Mark D Wareing; Ashley B Lyon; Bao Lu; Craig Gerard; Sally R Sarawar
Journal:  J Leukoc Biol       Date:  2004-07-07       Impact factor: 4.962

10.  Distinct regulation of host responses by ERK and JNK MAP kinases in swine macrophages infected with pandemic (H1N1) 2009 influenza virus.

Authors:  Wei Gao; Wenkui Sun; Bingqian Qu; Carol J Cardona; Kira Powell; Marta Wegner; Yi Shi; Zheng Xing
Journal:  PLoS One       Date:  2012-01-18       Impact factor: 3.240

View more
  8 in total

1.  MEK1 regulates pulmonary macrophage inflammatory responses and resolution of acute lung injury.

Authors:  Matthew E Long; Ke-Qin Gong; William E Eddy; Joseph S Volk; Eric D Morrell; Carmen Mikacenic; T Eoin West; Shawn J Skerrett; Jean Charron; W Conrad Liles; Anne M Manicone
Journal:  JCI Insight       Date:  2019-12-05

2.  Spred2 Deficiency Exacerbates D-Galactosamine/Lipopolysaccharide -induced Acute Liver Injury in Mice via Increased Production of TNFα.

Authors:  Xu Yang; Masayoshi Fujisawa; Teizo Yoshimura; Toshiaki Ohara; Miwa Sato; Megumi Mino; Thar Htet San; Tong Gao; Steven L Kunkel; Akihiro Matsukawa
Journal:  Sci Rep       Date:  2018-01-09       Impact factor: 4.379

3.  Spred2 Regulates High Fat Diet-Induced Adipose Tissue Inflammation, and Metabolic Abnormalities in Mice.

Authors:  Takahiro Ohkura; Teizo Yoshimura; Masayoshi Fujisawa; Toshiaki Ohara; Rie Marutani; Kaya Usami; Akihiro Matsukawa
Journal:  Front Immunol       Date:  2019-01-22       Impact factor: 7.561

4.  Abrogated Caveolin-1 expression via histone modification enzyme Setdb2 regulates brain edema in a mouse model of influenza-associated encephalopathy.

Authors:  Natsuko Imakita; Masahiro Kitabatake; Noriko Ouji-Sageshima; Atsushi Hara; Shoko Morita-Takemura; Kei Kasahara; Akihiro Matsukawa; Akio Wanaka; Keiichi Mikasa; Toshihiro Ito
Journal:  Sci Rep       Date:  2019-01-22       Impact factor: 4.379

5.  Expression of Spred2 in the urothelial tumorigenesis of the urinary bladder.

Authors:  Shinsuke Oda; Masayoshi Fujisawa; Li Chunning; Toshihiro Ito; Takahiro Yamaguchi; Teizo Yoshimura; Akihiro Matsukawa
Journal:  PLoS One       Date:  2021-11-24       Impact factor: 3.240

6.  Identification of Nifurtimox and Chrysin as Anti-Influenza Virus Agents by Clinical Transcriptome Signature Reversion.

Authors:  Yijing Xin; Shubing Chen; Ke Tang; You Wu; Ying Guo
Journal:  Int J Mol Sci       Date:  2022-02-21       Impact factor: 5.923

7.  Systematic optimization of host-directed therapeutic targets and preclinical validation of repositioned antiviral drugs.

Authors:  Dafei Xie; Song He; Lu Han; Lianlian Wu; Hai Huang; Huan Tao; Pingkun Zhou; Xunlong Shi; Hui Bai; Xiaochen Bo
Journal:  Brief Bioinform       Date:  2022-05-13       Impact factor: 13.994

Review 8.  Progress in experimental research on SPRED protein family.

Authors:  Jian Gong; Zhangren Yan; Qiao Liu
Journal:  J Int Med Res       Date:  2020-08       Impact factor: 1.671

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.